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Introduction. Since 2004 many treatment episodes in different stages of status epilepticus (SE) have been 
reported. Nowadays the use of levetiracetam (LEV) is recommended as a second-line treatment of SE, 
when the use of a benzodiazepine was not successful. 
Aim. The evidence based on randomized controlled trials for the application of a particular weight-based 
dose of LEV as a second-line treatment in benzodiazepine refractory SE is investigated.
Methods. Pubmedsearches were undertaken using the terms “Levetiracetam-status-epilepticus-trials” 
and “Levetiracetam-status-randomized” on May 8th 2021. We identified 17 studies reporting treatment 
with LEV as second line treatment and reporting dosages in mg/kg body weight. We grouped the studies 
according to the reported dosages (i.e. 20–25 mg/kg; 30 mg/kg; 40 mg/kg, 60 mg/kg). For each group we 
calculated the mean efficacy rate and the standard deviation of the efficacy rate weighted for the number 
of cases in the different studies. Twelve studies compared LEV with 20 mg/kg phenytoin (PHT). In these 
studies, we analysed the relative efficacy rate in comparison to PHT with the same procedure.
Results. Seven studies used LEV 20–25 mg/kg, two studies 30 mg/kg, six studies 40 mg/kg and one study 
60 mg/kg. Efficacy rate was highest in the group given 30 mg/kg (95% CI 87.5–90.1%). The relative effica-
cy rate with this weight-based dose was 1.12. This is just above the upper range of the 95% CI of the rela-
tive efficacy rate in studies using 40 mg/kg LEV (i.e. 1.11). The relative efficacy rates in the two other groups 
were considerably lower. 
Conclusion. According to the randomized controlled trials published so far a weight-based dose of 30–40 
mg/kg LEV may be appropriate for the treatment of benzodiazepine-refractory SE.
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INTRODUCTION
Since 2004 (Arrigo et al., 2004) many reports on the 
treatment of status epilepticus (SE) with levetiracetam 
(LEV) have been published. Based on a Pub-Med search 
on December 12th, 2011, 37 case series with 727 treat-
ment episodes were analysed in 2013 (Rösche et al., 
2013) and the efficacy rate of LEV in terminating SE 
was estimated to be in a range between 53.7 and 58.1%. 
Dosages ranged from 500 mg to 9000 mg/day and were 
rarely reported in mg/kg. LEV had been used in all 
stages of SE. In an up-date in 2019 (Rösche et al., 2019) 
based on a new Pub-Med search on July 6th, 2018, addi-
tionally 13 case series or prospective studies with 412 
treatment episodes were analysed and the efficacy rate 
of LEV was assessed as 55.0–59.4%. Eleven of the pa-
pers reported dosages in mg/kg and it was suspected 
that a loading dose of 30 mg/kg would be reasonable. 
Nowadays the use of LEV is recommended as sec-
ond-line treatment of SE, when the use of a benzodiaz-* There were no grants or other supports for this paper.
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epine was not successful (Rosenow et al., 2020). Based 
on the interim analysis of the study by Chamberlain 
et al. (2020) presented by Kapur et al. (2019) a weight-
based dose of 60 mg/kg was recommended. 
AIM
The evidence based on randomized controlled trials 
for the application of a particular weight-based dose 
of LEV as a second-line treatment in benzodiazepine 
refractory SE is investigated.
METHOD
Pub-Med Searches with the terms “Levetiracetam-sta-
tus-epilepticus-trials” and “Levetiracetam-status-ran-
domized” on May 8th, 2021, revealed 137 plus 118 re-
sults. After excluding studies not reporting treatment 
with LEV as second line treatment and those not re-
porting dosages in mg/kg body weight, 17 studies re-
mained. We grouped the studies according to the re-
ported dosages (i.e. 20–25 mg/kg; 30 mg/kg; 40 mg/kg, 
60 mg/kg). For each group we calculated the mean ef-
ficacy rate and the standard deviation of the efficacy 
rate weighted for the number of cases in the different 
studies. By this we calculated the 95% CI for the mean 
efficacy rates across the studies in each dosage group. 
Twelve studies compared LEV with 20 mg/kg pheny-
toin (PHT). In these studies, we analysed the relative 
efficacy rate in comparison to PHT. This was done by 
dividing the efficacy rate of LEV by the efficacy rate of 
PHT in each study. Then we calculated for each group 
the mean relative efficacy rate and the standard devia-
tion of the relative efficacy rate weighted for the num-
ber of cases in the different studies. By this we calculat-
ed the 95% CI for the mean relative efficacy rates across 
the studies in each dosage group.
RESULTS
Nine studies were conducted in paediatric patients 
only. The mean age of patients in these studies ranged 
from 2.5 years (Nalisetty et al., 2020) to 4.9 years (Na-
zir et al., 2020). Just eight studies included adults or el-
derly people. In two of them, the mean age of patients 
was between 61.5 and 68.5 years (Wongjirattikarn et 
al., 2019; Nene et al., 2019). In 5 other studies the mean 
age ranged from 34.8 years (Mundlamuri et al., 2015) to 
39.2 years (Misra et al., 2012). In the study by Chamber-
lain et al. (2020) the mean age of children was 6.1 years 
of adults 42.6 years and of older adults 73.8 years. Ka-
pur et al. (2019) reported an interim analysis of Cham-
berlain et al. (2020). Therefore, this study was exclud-
ed from the statistical analysis. Six studies reported 
the treatment of generalized convulsive SE exclusively. 
Only two studies (Dalziel et al., 2019, Chamberlain et 
al., 2020) were not in the 20–25 mg/group.
No study included patients with absence status ep-
ilepticus. Seven studies applied LEV 20–25 mg/kg 
(table 1), two studies 30 mg/kg (table 2), six studies 40 
mg/kg (table 3) and one study 60 mg/kg (table 4). From 
the study of Misra et al. (2012) only the subgroup of pa-
tients, who were treated because of ongoing seizure ac-
tivity 10 minutes after the administration of LZP, was 
included. As can be seen in figure 1 efficacy rate was 
highest in the group given 30 mg/kg (95% CI 87.5–
90.1%). Only one study compared 22 patients given LEV 
30 mg/kg with 30 patients given PHT 20 kg/kg. The rel-
ative efficacy rate was 1.12 (figure 2). This is just above 
the upper range of the 95% CI of the relative efficacy 
rate in the six studies comparing the use of 40 mg/kg 
LEV with 20 mg/kg PHT (i.e. 1.11). The relative efficacy 
rates in the two other groups were considerably lower. 
DISCUSSION
Although it seems reasonable to compare efficacy rates 
of randomized controlled trials in a defined clinical 
setting, several limitations of our study must be high-
lighted.
First of all, the study populations are not comparable. 
Chamberlain et al. (2020) reported a higher efficacy rate 
in children than in adults and elderly people. All stud-
ies applying 40 mg/kg were performed in a paediatric 
setting. Therefore, the high efficacy rates in this group 
may lead to an overestimation of the efficacy rates in 
adults and elderly. However, the relative efficacy rate in 
the subgroup of children given 60 mg/kg was 1.06, this 
was still lower than the lower limit of the 95% CI in the 
40 mg/kg group (i.e. 1.09). One reason for the higher ef-
ficacy rates in paediatric patients may be the inclusion 
of episodes with febrile SE. On the other hand, apart 
from the older adults in the study by Chamberlain et 
al. (2020) the eldest patients were in the 20–25 mg/kg 
group (Wongjirattikarn et al., 2019; Nene et al., 2019). 
But out of the three other studies of adult patients in 
this group (Misra et al., 2012; Mundlamuri et al., 2015; 
Chakravarthi et al., 2015) only Mundlamuri et al. (2015) 
reported a higher efficacy rate. Therefor the low effica-
cy rate in the 20–25 mg/kg group cannot be explained 
by the inclusion of elderly patients.
It has to be emphasised that the efficacy rates were 
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lower in studies of treatment of generalized convulsive 
SE only. A subgroup analysis of the four studies of gen-
eralized SE only in the 20–25 mg/kg group (Mundla-
muri et al., 2015; Chakravarthi et al., 2015; Nene et al., 
2019; Nazir et al., 2020) reveals a mean efficacy rate of 
74.43% (SD 5.99%). The only study focussing on gener-
alized convulsive SE in the 40 mg/kg group (Dalziel et 
al., 2019) had an efficacy rate of 50%. This is not much 
above the efficacy rate in the group of children report-
ed by Chamberlain et al. (2020). But it is questionable 
whether the difference in types of SE is crucial for the 
different results because in a retrospective study com-
paring four intravenously applied antiseizure medica-
tions (ASMs) according to four different efficacy cri-
teria, no criterion revealed a significant difference of 
efficacy rate of a specific ASMs in different types of 
SE (Redecker et al., 2017). The low efficacy rate in the 
study by Dalziel et al. (2019) may be a result of the ef-
ficacy criterion as well (see below).
Another problem may be that the published dos-
es were not applied to all patients because the weight-
based dosing was capped at a certain body weight. In 
the ESETT trial (Chamberlain et al., 2020) this was the 
case at a body weight of 75 kg. Since in this trial 48.2% 
of adults and 0.9% of children only had a higher body 
weight the really applied weight-based dose was obvi-
ously lower in adults than in children (Sathe et al., 2020). 
But at least in the adults the efficacy rate of LEV was 
not significantly lower in patients with a body weight 
higher than 75 kg than in the others. From this it may 
be suspected that lower weight-based doses than 60 
mg/kg may be at least equally effective. Another prob-
lem may be consequent to the different outcome crite-
ria. From preclinical data it is reasonable to assume that 
after intravenously application of LEV 1500 mg peak 
concentrations in the brain occur as late as after one 
hour (Nicolas et al., 2016). This may be an explanation 
for the results of Navarro et al. (2016), who found no 
superiority of 2500 mg LEV given immediately after 
1 mg clonazepam over placebo when evaluated 9 min-
utes after the end of the infusion. As can be seen in ta-
ble 3 one of the studies applying 40 mg/kg LEV evalu-


















Figure 2. Relative efficacy rates in comparison to 20 mg/kg Phenytoin of 
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ated the treatment effect five minutes after completion 
of the infusion (Dalziel et al., 2019) and had by far the 
lowest efficacy rate in this group (i.e. 50%). But even 
this was slightly higher than the efficacy rate in adults 
or elderly one hour after start of infusion of 60 mg/kg 
(Chamberlain et al., 2020). Therefore, the different out-
come criteria may not explain the differences of effi-
cacy rates between the groups of studies with different 
weight-based doses. 
CONCLUSION
According to the randomized controlled trials pub-
lished so far, a weight-based dose of 30–40 mg/kg LEV 
may be appropriate for the treatment of benzodiaz-
epine-refractory SE. It may be more efficacious than 
PHT in these doses. This is in line with a review pub-
lished in 2014 (Yasiry and Shorvon, 2014).
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